Summary
25.19 0.60(2.44%)08/28/2024
Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NRIX)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| 2.40 | 5.51 | 18.01 | 62.05 | 111.41 | 192.23 | 0.00 | 32.51 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 25.19 | |
| Open | 24.61 | |
| High | 25.40 | |
| Low | 24.00 | |
| Volume | 311,617 | |
| Change | 0.59 | |
| Change % | 2.40 | |
| Avg Volume (20 Days) | 341,123 | |
| Volume/Avg Volume (20 Days) Ratio | 0.91 | |
| 52 Week Range | 4.22 - 26.12 | |
| Price vs 52 Week High | -3.56% | |
| Price vs 52 Week Low | 496.92% | |
| Range | 2.36 | |
| Gap Up/Down | -1.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 1,584 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 51.00 | |
| Book Value | 8.4210 | |
| Earnings Per Share | -2.4020 | |
| EPS Estimate Current Quarter | -0.6200 | |
| EPS Estimate Next Quarter | 0.0000 | |
| EPS Estimate Current Year | -2.5800 | |
| EPS Estimate Next Year | -3.0800 | |
| Diluted EPS (TTM) | -2.4020 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -3.4411 | |
| Return on asset (TTM) | -0.1381 | |
| Return on equity (TTM) | -0.2912 | |
| Revenue TTM | 29,043,000 | |
| Revenue per share TTM | 0.7020 | |
| Quarterly Revenue Growth (YOY) | 1.5100 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | -48,674,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3957 | |
| Revenue Enterprise Value | 32.0297 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 44,612,600 | |
| Shares Float | 34,803,664 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 2.54 | |
| Institutions (%) | 89.33 | |
07/25 10:56 EST - zacks.com
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
How Much Upside is Left in Nurix Therapeutics (NRIX)? Wall Street Analysts Think 25.27%
The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 25.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
07/16 13:05 EST - zacks.com
Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are You Looking for a Top Momentum Pick? Why Nurix Therapeutics, Inc. (NRIX) is a Great Choice
Does Nurix Therapeutics, Inc. (NRIX) have what it takes to be a top stock pick for momentum investors? Let's find out.
07/11 18:10 EST - zacks.com
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.45 per share a year ago.
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $0.45 per share a year ago.
07/11 16:00 EST - globenewswire.com
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL
Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL
06/19 06:05 EST - zacks.com
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nurix Therapeutics (NRIX) Surges 20.6%: Is This an Indication of Further Gains?
Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
05/28 07:00 EST - globenewswire.com
Nurix Therapeutics Appoints Paula G. O'Connor, M.D.
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies
Nurix Therapeutics Appoints Paula G. O'Connor, M.D.
Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies Expanded C-level team poised to accelerate development of NX-5948 in B cell malignancies
05/20 16:00 EST - globenewswire.com
Nurix Therapeutics Announces Board Chair Transition
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L.
Nurix Therapeutics Announces Board Chair Transition
David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory unanimously elected new board chair SAN FRANCISCO, May 20, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that the chair of its board of directors, David L.
05/14 10:00 EST - globenewswire.com
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced an upcoming oral presentation highlighting new clinical data from Nurix's orally available, selective BTK degrader, NX-5948, at the European Hematology Association Congress which is being held from June 13 - 16, 2024, in Madrid, Spain, and virtually. The presentation will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, including patients with BTK inhibitor resistance mutations and CNS involvement.
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations to BTK inhibitors The oral presentation at EHA will include additional data at higher dose levels and longer treatment durations Company will host a webcast conference call on June 16 following the data presentation at EHA (details to follow) SAN FRANCISCO, May 14, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced an upcoming oral presentation highlighting new clinical data from Nurix's orally available, selective BTK degrader, NX-5948, at the European Hematology Association Congress which is being held from June 13 - 16, 2024, in Madrid, Spain, and virtually. The presentation will summarize updated data from the ongoing Phase 1a/b study of NX-5948 in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, including patients with BTK inhibitor resistance mutations and CNS involvement.
05/07 07:00 EST - globenewswire.com
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 2024 RBC Capital Markets Global Healthcare Conference at 9:30-9:55 a.m. ET, on Tuesday, May 14, 2024.
04/16 18:21 EST - globenewswire.com
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. In addition, and in lieu of common stock, Nurix sold to certain investors pre-funded warrants to purchase 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $188.6 million.
Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
SAN FRANCISCO, April 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the closing of its underwritten public offering of 11,916,667 shares of its common stock at a public offering price of $15.00 per share, which includes 1,750,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock. In addition, and in lieu of common stock, Nurix sold to certain investors pre-funded warrants to purchase 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The net proceeds from the offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $188.6 million.
04/11 23:38 EST - globenewswire.com
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $175.0 million. Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock in connection with the public offering. The offering is expected to close on or about April 16, 2024, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Nurix.
Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX) today announced the pricing of its upsized underwritten public offering of 10,166,667 shares of its common stock at a price to the public of $15.00 per share. In addition, and in lieu of common stock, Nurix is offering to certain investors pre-funded warrants to purchase up to an aggregate of 1,500,100 shares of common stock at a purchase price of $14.999 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to Nurix from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Nurix, are expected to be $175.0 million. Nurix has granted the underwriters a 30-day option to purchase up to an additional 1,750,000 shares of common stock in connection with the public offering. The offering is expected to close on or about April 16, 2024, subject to the satisfaction of customary closing conditions. All of the securities are being offered by Nurix.
04/11 16:00 EST - globenewswire.com
Nurix Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions. All of the securities will be offered and sold by Nurix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Nurix Therapeutics Announces Proposed Public Offering
SAN FRANCISCO, April 11, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that it has commenced an underwritten public offering of $125 million of its common stock and, in lieu of common stock, in the case of certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Nurix intends to grant the underwriters a 30-day option to purchase additional shares of its common stock at the public offering price less underwriting discounts and commissions. All of the securities will be offered and sold by Nurix. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
04/10 10:31 EST - zacks.com
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
04/10 09:11 EST - zacks.com
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.75 per share a year ago.
Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates
Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.75 per share a year ago.
04/10 07:00 EST - globenewswire.com
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies on NX-5948 demonstrating clinical responses in patients with CNS lymphoma and CLL with CNS involvement Announced that it is part of a team of experts selected as awardees in this year's Cancer Grand Challenges SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update. “Nurix had a strong start to 2024 with the recent announcements of the extensions of our collaborations with both Gilead and Sanofi further validating the power of our platform and the expansion of our work in inflammatory diseases with Sanofi, including the STAT6 program, one of the most exciting targets in inflammation,” said Arthur T.
Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update
Extended the Strategic Collaboration with Gilead Sciences Extended the Strategic Collaboration with Sanofi to Develop Novel Orally Available Targeted Protein Degrader of STAT6 Presented new case studies on NX-5948 demonstrating clinical responses in patients with CNS lymphoma and CLL with CNS involvement Announced that it is part of a team of experts selected as awardees in this year's Cancer Grand Challenges SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today reported financial results for the first quarter ended February 29, 2024, and provided a corporate update. “Nurix had a strong start to 2024 with the recent announcements of the extensions of our collaborations with both Gilead and Sanofi further validating the power of our platform and the expansion of our work in inflammatory diseases with Sanofi, including the STAT6 program, one of the most exciting targets in inflammation,” said Arthur T.
04/09 13:15 EST - globenewswire.com
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement
Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies
Presented new case studies demonstrating clinical responses in two patients with B cell malignancies, chronic lymphocytic leukemia (CLL) and primary central nervous system lymphoma (PCNSL), each with central nervous system (CNS) involvement
04/09 07:00 EST - globenewswire.com
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation
Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6
Goal is to develop an oral STAT6 degrader investigational new drug with potential to address the needs of patients with type 2 inflammation
04/03 07:00 EST - globenewswire.com
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, Nurix's chief financial officer, and Jason Kantor, Ph.D., Nurix's chief business officer, will participate in the following conferences in April:
Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, April 03, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D, Ph.D., president and chief executive officer of Nurix, Hans van Houte, Nurix's chief financial officer, and Jason Kantor, Ph.D., Nurix's chief business officer, will participate in the following conferences in April:
04/02 07:00 EST - globenewswire.com
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up to $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies' ongoing collaboration, originally established in 2019, by an additional two years. “Gilead's extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
Two-year extension of ongoing research collaboration intended to generate multiple additional clinical candidates Nurix will receive a $15.0 million extension fee, and will remain eligible for up to an additional $73.5 million in potential preclinical research milestones and licensing fees, and up to $1.7 billion in potential future development, regulatory, and sales milestones as well as royalties on future products Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States SAN FRANCISCO, April 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Gilead Sciences has elected to extend the research term of the companies' ongoing collaboration, originally established in 2019, by an additional two years. “Gilead's extension of the research period of this agreement is a testament to the productivity of our collaboration to date.
03/25 07:00 EST - globenewswire.com
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer
Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)
Researchers will apply the latest TPD drug discovery technology to target fusion proteins that cause pediatric cancer